Special Issue

Hepatitis-Associated Liver Cancer

Message from the Guest Editors

Hepatocellular carcinoma (HCC) is one of the most common cancers, and the second cause of cancerrelated death worldwide. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major etiologies of HCC. Compared with non-hepatitis-associated liver cancer. hepatitis-associated liver cancer has definite high-risk groups and a high proportion of alpha-fetoprotein (AFP) elevation. Periodic surveillance with ultrasound and AFP results in a higher chance of early detection and curative treatment. HBV-related HCC is well controlled by HBV vaccination. Vaccinated cohorts demonstrate a significantly decreased HCC incidence, proving it to be a successful method of primary prevention. Nucleoside/nucleotide analogues (NUC) for HBV suppression and direct-acting anti-viral agents (DAA) for HCV eradication play a role in secondary prevention. For post-treatment HCC patients, both NUC and DAA preserve liver function and decrease the probability of tumor recurrence. Recently, several target and immune therapeutic agents have been launched... In this Special Issue, articles about hepatitis-associated liver cancer and comparisons between viral and non-viral HCC are invited.

Guest Editors

Prof. Dr. Sheng-Nan Lu

- 1. College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan
- Department of Gastroenterology and Hepatology, Division of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833401, Taiwan

Prof. Dr. Mei-Hsuan Lee

Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Deadline for manuscript submissions

closed (31 January 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/114152

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

